Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2016

01-01-2016 | Original Article

CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo

Authors: Xing-Xing He, Yu-Nan Zhang, Jun-Wei Yan, Jing-Jun Yan, Qian Wu, Yu-Hu Song

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

The tumor suppressor p53 is one of the most frequently mutated genes in hepatocellular carcinoma (HCC). Previous studies demonstrated that CP-31398 restored the native conformation of mutant p53 and trans-activated p53 downstream genes in tumor cells. However, the research on the application of CP-31398 to liver cancer has not been reported. Here, we investigated the effects of CP-31398 on the phenotype of HCC cells carrying p53 mutation. The effects of CP-31398 on the characteristic of p53-mutated HCC cells were evaluated through analyzing cell cycle, cell apoptosis, cell proliferation, and the expression of p53 downstream genes. In tumor xenografts developed by PLC/PRF/5 cells, the inhibition of tumor growth by CP-31398 was analyzed through gross morphology, growth curve, and the expression of p53-related genes. Firstly, we demonstrated that CP-31398 inhibited the growth of p53-mutated liver cancer cells in a dose-dependent and p53-dependent manner. Then, further study showed that CP-31398 re-activated wild-type p53 function in p53-mutated HCC cells, which resulted in inhibitive response of cell proliferation and an induction of cell-cycle arrest and apoptosis. Finally, in vivo data confirmed that CP-31398 blocked the growth of xenografts tumors through transactivation of p53-responsive downstream molecules. Our results demonstrated that CP-31398 induced desired phenotypic change of p53-mutated HCC cells in vitro and in vivo, which revealed that CP-31398 would be developed as a therapeutic candidate for HCC carrying p53 mutation.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of hcc. J Hepatol. 2012;56 Suppl 1:S75–87.CrossRefPubMed
3.
4.
5.
6.
7.
Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR. Characterization of the p53-rescue drug cp-31398 in vitro and in living cells. Oncogene. 2002;21:2119–29.CrossRefPubMed
8.
He X, Liu F, Yan J, Zhang Y, Shang H, Dou Q. Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo. Sci Rep. 2015;5:8705.CrossRefPubMedPubMedCentral
9.
He X, Liao J, Liu F, Yan J, Shang H, Dou Q, et al. Functional repair of p53 mutation in colorectal cancer cells using trans-splicing. Oncotarget. 2015;6:2034–45.CrossRefPubMed
10.
Sell S. Mouse models to study the interaction of risk factors for human liver cancer. Cancer Res. 2003;63:7553–62.PubMed
11.
Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047–63.CrossRefPubMed
12.
Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, et al. Alterations of tp53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer. 2012;48:2328–38.CrossRefPubMedPubMedCentral
13.
Bossi G, Sacchi A. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck. 2007;29:272–84.CrossRefPubMed
14.
15.
North S, El-Ghissassi F, Pluquet O, Verhaegh G, Hainaut P. The cytoprotective aminothiol wr1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene. 2000;19:1206–14.CrossRefPubMed
16.
Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002;8:282–8.CrossRefPubMed
17.
Peng Y, Li C, Chen L, Sebti S, Chen J. Rescue of mutant p53 transcription function by ellipticine. Oncogene. 2003;22:4478–87.CrossRefPubMed
18.
Demma MJ, Wong S, Maxwell E, Dasmahapatra B. Cp-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J Biol Chem. 2004;279:45887–96.CrossRefPubMed
19.
Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, et al. Small molecule rita binds to p53, blocks p53-hdm-2 interaction and activates p53 function in tumors. Nat Med. 2004;10:1321–8.CrossRefPubMed
20.
Zache N, Lambert JM, Rokaeus N, Shen J, Hainaut P, Bergman J, et al. Mutant p53 targeting by the low molecular weight compound stima-1. Mol Oncol. 2008;2:70–80.CrossRefPubMed
21.
22.
Fiorini C, Menegazzi M, Padroni C, Dando I, Dalla Pozza E, Gregorelli A, et al. Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis. Apoptosis Int J Prog Cell Death. 2013;18:337–46.CrossRef
23.
Rao CV, Patlolla JM, Qian L, Zhang Y, Brewer M, Mohammed A, et al. Chemopreventive effects of the p53-modulating agents cp-31398 and prima-1 in tobacco carcinogen-induced lung tumorigenesis in a/j mice. Neoplasia. 2013;15:1018–27.CrossRefPubMedPubMedCentral
24.
Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, el-Deiry WS. The mutant p53-conformation modifying drug, cp-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther. 2002;1:47–55.CrossRefPubMed
25.
Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR, et al. Cp-31398 restores mutant p53 tumor suppressor function and inhibits uvb-induced skin carcinogenesis in mice. J Clin Invest. 2007;117:3753–64.CrossRefPubMedPubMedCentral
26.
Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H, et al. Targeting wild-type and mutant p53 with small molecule cp-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res. 2010;70:6566–76.CrossRefPubMedPubMedCentral
27.
He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, et al. Microrna-375 targets aeg-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31:3357–69.CrossRefPubMed
28.
Wang Z, Liu F, Tu W, Chang Y, Yao J, Wu W, et al. Embryonic liver fodrin involved in hepatic stellate cell activation and formation of regenerative nodule in liver cirrhosis. J Cell Mol Med. 2012;16:118–28.CrossRefPubMed
29.
Wang Z, Song Y, Tu W, He X, Lin J, Liu F. Beta-2 spectrin is involved in hepatocyte proliferation through the interaction of tgfbeta/smad and pi3k/akt signalling. Liver Int Off J Int Assoc Stud Liver. 2012;32:1103–11.CrossRef
30.
He X, Kong X, Yan J, Zhang Y, Wu Q, Chang Y, et al. Cp-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo. Tumour Biol J Int Soc Oncodev Biol Med. 2015;36:1437–44.CrossRef
31.
Lehmann BD, Pietenpol JA. Targeting mutant p53 in human tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:3648–50.CrossRef
32.
33.
Levesque AA, Eastman A. P53-based cancer therapies: is defective p53 the achilles heel of the tumor? Carcinogenesis. 2007;28:13–20.CrossRefPubMed
34.
Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science. 1999;286:2507–10.CrossRefPubMed
35.
Wang W, Takimoto R, Rastinejad F, El-Deiry WS. Stabilization of p53 by cp-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or mdm2 binding. Mol Cell Biol. 2003;23:2171–81.CrossRefPubMedPubMedCentral
36.
Roh JL, Kang SK, Minn I, Califano JA, Sidransky D, Koch WM. P53-reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol. 2011;47:8–15.CrossRefPubMed
Metadata
Title
CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo
Authors
Xing-Xing He
Yu-Nan Zhang
Jun-Wei Yan
Jing-Jun Yan
Qian Wu
Yu-Hu Song
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3857-5

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue

Original Article

The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease

Original Article

miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1

Original Article

PTEN gene polymorphisms and susceptibility to oral squamous cell carcinoma in a Chinese Han population

Original Article

Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens

Original Article

Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia

Original Article

Staphylococcal enterotoxin B/texosomes as a candidate for breast cancer immunotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits